Rekombinanter TAG-72 (Minretumomab Biosimilar) Antikörper

Produktnummer ABIN7072523

Der Maus Monoklonal Anti-TAG-72 (Minretumomab Biosimilar)-Antikörper wurde für FACS, IHC, RIA und WB validiert. Er ist geeignet, TAG-72 (Minretumomab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter TAG-72 (Minretumomab Biosimilar) Antikörper (ABIN7072523)

Target: TAG-72 (Minretumomab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TAG-72 (Minretumomab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunohistochemistry (IHC), Radioimmunoassay (RIA), Western Blotting (WB)

Produktdetails anti-TAG-72 (Minretumomab Biosimilar) Antikörper

Verwendungszweck: Anti-TAG-72 [Minretumomab (CC49 )], Mouse IgG1, kappa

Spezifität: This antibody is specific for the disaccharide sialyl Tn epitope of human TAG-72. TAG-72 is expressed on a wide range of human carcinomas, including colorectal cancers.

Produktmerkmale:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: This antibody was raised by immunising BALB/c mice with TAG-72 purified from LS-174T human carcinoma xenograft.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: The reactivity of this antibody with colon cancer extract and purified TAG-72 has been confirmed in solid-phase radioimmunoassays, and its reactivity with formalin-fixed carcinoma tissue sections confirmed in immunoperoxidase studies (Muraro et al, 1988). In flow cytometric analysis of freshly-isolated human carcinoma cells, this antibody reacts more strongly than the anti-TAG-72 MAb B72.3 (Muraro et al, 1988). Equally, flow cytometric analyses using this antibody have revealed that TAG-72 is expressed by certain haematopoietic cell lines (Nicolet et al, 1997). In western blot analysis, this antibody reacts with TAG-72 (Muraro et al, 1988). A humanised version of this antibody has been shown to be safe and sensitive in detecting recurrent colorectal carcinomas in radioimmunoguided surgery (Agnese et al, 2004), while radioimmunotherapy with an iodine-131-conjugated antibody has been shown to have a significant therapeutic effect on metastatic colon carcinoma in Phase I trials (Divgi et al, 1995).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu TAG-72 (Minretumomab Biosimilar)

Target: TAG-72 (Minretumomab Biosimilar)

Hintergrund: CA 72-4, Tumor-associated antigen 72, TAG72, Tumor-associated glycoprotein 72